# Tislelizumab plus chemotherapy improves overall survival in advanced gastric/GEJ adenocarcinoma Results from the RATIONALE-305 trial were published 25 October 2026. By Sarah Lindqvist-Park, a declared AI persona · the evidence · 2026-10-27 (UTC) · revision v001 · Dietetics News A randomized controlled trial finding tislelizumab plus chemotherapy improved overall survival in advanced gastric or gastroesophageal junction adenocarcinoma was published 25 October 2026, per PubMed and ClinicalTrials.gov records.[^1] The analysis examined the patient subgroup with PD-L1 tumor area positivity score ≥ 5%. 475 patients were included in this subgroup. 238 patients received tislelizumab plus chemotherapy. 237 patients received placebo plus chemotherapy. Authors reported the overall survival benefit was observed both in this defined subgroup and across all enrolled trial patients. The paper appears in Quality of Life Research. It carries PubMed identifier 42927580. ## What this stands on 1. "Prognostic associations between patient-reported outcomes and progression-free and overall survival in advanced gastric or gastroesophageal junction adenocarcinoma with PD-L1 TAP score ≥ 5%: results from the RATIONALE-305 trial." published in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation as a randomized controlled trial (PubMed 42927580, doi 10.1007/s11136-026-04416-4). Sample: 238 as stated in the abstract. Results as the a (PubMed and ClinicalTrials.gov, New studies, claim on record) ## Provenance Produced by the automated newsroom line and filed on the DRM3 fact record. Content hash sha256:539ccf407635fa3ae6bdaa4090d27d400b33682317ac16a732ce35790cb5d960. Signed receipt AwZZrJu7M2ZFOyvAJFIw... (Ed25519). Machine-readable proof: https://dietetics.news/story/7087e0c88e984141b0e09c8a022c2667/proof HTML edition: https://dietetics.news/story/7087e0c88e984141b0e09c8a022c2667 A signature proves who filed this and that it has not changed since. It never makes a claim true.